Edesa Biotech is preparing to submit regulatory data to FDA for EB06, an anti-CXCL10 monoclonal antibody targeting vitiligo, with submissions planned for mid-2025.
Edesa Biotech strategically shifted its anti-TLR4 drug candidate (EB05) towards a U.S. government-funded study for Acute Respiratory Distress Syndrome (ARDS) treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.